[Guideline] Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008 May 27. 51(21):e1-62. [Medline].
Kamphuis HC, de Leeuw JR, Derksen R, Hauer RN, Winnubst JA. Implantable cardioverter defibrillator recipients: quality of life in recipients with and without ICD shock delivery: a prospective study. Europace. 2003 Oct. 5(4):381-9. [Medline].
Mirowski M, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med. 1980 Aug 7. 303(6):322-4. [Medline].
Robinson LA, Windle JR, Easley AR. Options in managing the patient with high defibrillation thresholds. Ann Thorac Surg. 1994 May. 57(5):1184-92. [Medline].
Bardy GH, Poole JE, Kudenchuk PJ, et al. A prospective randomized comparison in humans of biphasic waveform 60-microF and 120-microF capacitance pulses using a unipolar defibrillation system. Circulation. 1995 Jan 1. 91(1):91-5. [Medline].
Kroll MW, Swerdlow CD. Optimizing defibrillation waveforms for ICDs. J Interv Card Electrophysiol. 2007 Apr. 18(3):247-63. [Medline].
U.S. Food and Drug Administration. FDA approves first subcutaneous heart defibrillator. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm321755.htm. Accessed: September 28, 2012.
Wever EF, Hauer RN, van Capelle FL, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation. 1995 Apr 15. 91(8):2195-203. [Medline].
The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997 Nov 27. 337(22):1576-83. [Medline].
Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000 Mar 21. 101(11):1297-302. [Medline].
Bokhari F, Newman D, Greene M, Korley V, Mangat I, Dorian P. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation. 2004 Jul 13. 110(2):112-6. [Medline].
Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000 Aug 15. 102(7):748-54. [Medline].
Siebels J, Kuck KH. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J. 1994 Apr. 127(4 Pt 2):1139-44. [Medline].
Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial (MADIT) Investigators. N Engl J Med. 1996 Dec 26. 335(26):1933-40. [Medline].
Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial (MUSTT) Investigators. N Engl J Med. 1999 Dec 16. 341(25):1882-90. [Medline].
Buxton AE, Lee KL, Hafley GE, et al. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the multicenter unsustained tachycardia trial. Circulation. 2002 Nov 5. 106(19):2466-72. [Medline].
Fisher JD, Buxton AE, Lee KL, et al. Designation and distribution of events in the Multicenter UnSustained Tachycardia Trial (MUSTT). Am J Cardiol. 2007 Jul 1. 100(1):76-83. [Medline].
Moss AJ, Zareba W, Hall WJ. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction (MADIT II). N Engl J Med. 2002 Mar 21. 346(12):877-83. [Medline].
Zwanziger J, Hall WJ, Dick AW, Zhao H, Mushlin AI, Hahn RM, et al. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006 Jun 6. 47(11):2310-8. [Medline].
Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004 May 20. 350(21):2140-50. [Medline].
Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 Jan 20. 352(3):225-37. [Medline].
Adabag S, Roukoz H, Anand IS, Moss AJ. Cardiac resynchronization therapy in patients with minimal heart failure a systematic review and meta-analysis. J Am Coll Cardiol. 2011 Aug 23. 58(9):935-41. [Medline].
Levy WC, Lee KL, Hellkamp AS, Poole JE, Mozaffarian D, Linker DT, et al. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation. 2009 Sep 8. 120(10):835-42. [Medline].
Santangeli P, Pelargonio G, Russo AD, Casella M, Bisceglia C, Bartoletti S. Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: A systematic review and meta-analysis. Heart Rhythm. 2010 Jul. 7(7):876-882. [Medline].
Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004 May 20. 350(21):2151-8. [Medline].
Bänsch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002 Mar 26. 105(12):1453-8. [Medline].
Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997 Nov 27. 337(22):1569-75. [Medline].
Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004 Dec 9. 351(24):2481-8. [Medline].
Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. J Am Coll Cardiol. 2003 May 21. 41(10):1707-12. [Medline].
Barsheshet A, Moss AJ, Eldar M, et al. Time-dependent benefit of preventive cardiac resynchronization therapy after myocardial infarction. Eur Heart J. 2011 Jul. 32(13):1614-21. [Medline].
Pouleur AC, Barkoudah E, Uno H, Skali H, Finn PV, Zelenkofske SL, et al. Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation. 2010 Aug 10. 122(6):597-602. [Medline].
Santangeli P, Di Biase L, Dello Russo A, Casella M, Bartoletti S, Santarelli P. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators. Ann Intern Med. 2010 Nov 2. 153(9):592-9. [Medline].
Healey JS, Hallstrom AP, Kuck KH, Nair G, Schron EP, Roberts RS, et al. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. Eur Heart J. 2007 Jul. 28(14):1746-9. [Medline].
Wilcox JE, Fonarow GC, Zhang Y, et al. Clinical effectiveness of cardiac resynchronization and implantable cardioverter-defibrillator therapy in men and women with heart failure: findings from IMPROVE HF. Circ Heart Fail. 2014 Jan. 7 (1):146-53. [Medline].
Pokorney SD, Hellkamp AS, Yancy CW, et al. Primary prevention implantable cardioverter-defibrillators in older racial and ethnic minority patients. Circ Arrhythm Electrophysiol. 2015 Feb. 8 (1):145-51. [Medline].
Erkapic D, Sperzel J, Stiller S, Meltendorf U, Mermi J, Wegscheider K, et al. Long-term benefit of implantable cardioverter/defibrillator therapy after elective device replacement: results of the INcidence free SUrvival after ICD REplacement (INSURE) trial--a prospective multicentre study. Eur Heart J. 2012 Jul 6. [Medline].
Zareba W, Moss AJ, Daubert JP, et al. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol. 2003 Apr. 14(4):337-41. [Medline].
Viskin S. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol. 2003 Oct. 14(10):1130-1; reply 1131. [Medline].
Goel AK, Berger S, Pelech A, et al. Implantable cardioverter defibrillator therapy in children with long QT syndrome. Pediatr Cardiol. 2004 Jul-Aug. 25(4):370-8. [Medline].
Monnig G, Kobe J, Loher A, et al. Implantable cardioverterdefibrillator therapy in patients with congenital long-QT syndrome: a long-term follow-up. Heart Rhythm. 2005. 2:497-504.
Goldenberg I, Mathew J, Moss AJ, et al. Corrected QT variability in serial electrocardiograms in long QT syndrome: the importance of the maximum corrected QT for risk stratification. J Am Coll Cardiol. 2006 Sep 5. 48(5):1047-52. [Medline].
Hobbs JB, Peterson DR, Moss AJ, et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA. 2006 Sep 13. 296(10):1249-54. [Medline].
Ghanbari H, Phard WS, Al-Ameri H, Latchamsetty R, Jongnarngsin K, Crawford T, et al. Meta-Analysis of Safety and Efficacy of Uninterrupted Warfarin Compared to Heparin-Based Bridging Therapy During Implantation of Cardiac Rhythm Devices. Am J Cardiol. 2012 Aug 17. [Medline].
Bernstein AD, Daubert JC, Fletcher RD, Hayes DL, Lüderitz B, Reynolds DW, et al. The revised NASPE/BPEG generic code for antibradycardia, adaptive-rate, and multisite pacing. North American Society of Pacing and Electrophysiology/British Pacing and Electrophysiology Group. Pacing Clin Electrophysiol. 2002 Feb. 25(2):260-4. [Medline].
McMullan J, Valento M, Attari M, Venkat A. Care of the pacemaker/implantable cardioverter defibrillator patient in the ED. Am J Emerg Med. 2007 Sep. 25(7):812-22. [Medline].
Lampert R, Hayes DL, Annas GJ, Farley MA, Goldstein NE, Hamilton RM, et al. HRS Expert Consensus Statement on the Management of Cardiovascular Implantable Electronic Devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy This document was developed in collaboration and endorsed by the American College of Cardiology (ACC), the American Geriatrics Society (AGS), the American Academy of Hospice and Palliative Medicine (AAHPM); the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), and the Hospice and Palliative N... Heart Rhythm. 2010 Jul. 7(7):1008-26. [Medline].
Freeman JV, Wang Y, Curtis JP, Heidenreich PA, Hlatky MA. Physician procedure volume and complications of cardioverter-defibrillator implantation. Circulation. 2012 Jan 3. 125(1):57-64. [Medline].
Uslan DZ, Gleva MJ, Warren DK, et al. Cardiovascular Implantable Electronic Device Replacement Infections and Prevention: Results from the REPLACE Registry. Pacing Clin Electrophysiol. 2012 Jan. 35(1):81-87. [Medline].
Curtis JP, Luebbert JJ, Wang Y, et al. Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator. JAMA. 2009 Apr 22. 301(16):1661-70. [Medline].
Fischer A, Ousdigian KT, Johnson JW, Gillberg JM, Wilkoff BL. The impact of atrial fibrillation with rapid ventricular rates and device programming on shocks in 106,513 ICD and CRT-D patients. Heart Rhythm. 2012 Jan. 9(1):24-31. [Medline].
Daubert JP, Zareba W, Cannom DS, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. 2008 Apr 8. 51(14):1357-65. [Medline].
Bhavnani SP, Coleman CI, White CM, et al. Association between statin therapy and reductions in atrial fibrillation or flutter and inappropriate shock therapy. Europace. 2008 Jul. 10(7):854-9. [Medline].
Almendral J, Arribas F, Wolpert C, et al. Dual-chamber defibrillators reduce clinically significant adverse events compared with single-chamber devices: results from the DATAS (Dual chamber and Atrial Tachyarrhythmias Adverse events Study) trial. Europace. 2008 May. 10(5):528-35. [Medline].
Hauser RG, Kallinen LM, Almquist AK, et al. Early failure of a small-diameter high-voltage implantable cardioverter-defibrillator lead. Heart Rhythm. 2007 Jul. 4(7):892-6. [Medline]. [Full Text].
Kallinen LM, Hauser RG, Lee KW, et al. Failure of impedance monitoring to prevent adverse clinical events caused by fracture of a recalled high-voltage implantable cardioverter-defibrillator lead. Heart Rhythm. 2008 Jun. 5(6):775-9. [Medline].
Krahn AD, Champagne J, Healey JS, et al. Outcome of the Fidelis implantable cardioverter-defibrillator lead advisory: a report from the Canadian Heart Rhythm Society Device Advisory Committee. Heart Rhythm. 2008 May. 5(5):639-42. [Medline].
Faulknier BA, Traub DM, Aktas MK, et al. Time-dependent risk of Fidelis lead failure. Am J Cardiol. 2010 Jan 1. 105(1):95-9. [Medline].
Kallinen LM, Hauser RG, Tang C, et al. Lead integrity alert algorithm decreases inappropriate shocks in patients who have Sprint Fidelis pace-sense conductor fractures. Heart Rhythm. 2010 Aug. 7(8):1048-55. [Medline].
Swerdlow CD, Sachanandani H, Gunderson BD, et al. Preventing overdiagnosis of implantable cardioverter-defibrillator lead fractures using device diagnostics. J Am Coll Cardiol. 2011 Jun 7. 57(23):2330-9. [Medline].
Maytin M, Love CJ, Fischer A, et al. Multicenter experience with extraction of the Sprint Fidelis implantable cardioverter-defibrillator lead. J Am Coll Cardiol. 2010 Aug 17. 56(8):646-50. [Medline].
Morrison TB, Friedman PA, Kallinen LM, et al. Impact of implanted recalled sprint fidelis lead on patient mortality. J Am Coll Cardiol. 2011 Jul 12. 58(3):278-83. [Medline].
US Food & Drug Administration. Premature insulation failure in recalled Riata implantable cardioverter defibrillator (ICD) leads manufactured by St. Jude Medical, Inc.: FDA safety communication [archived]. Available at http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm314930.htm. January 12, 2015; Accessed: February 13, 2017.
Haines DE, Wang Y, Curtis J. Implantable cardioverter-defibrillator registry risk score models for acute procedural complications or death after implantable cardioverter-defibrillator implantation. Circulation. 2011 May 17. 123(19):2069-76. [Medline].
Undefined. [Medline].
Medtronic. Electromagnetic Compatibility Guide. Medtronic. Available at http://www.medtronic.com/rhythms/downloads/UC200602918EN.pdf.
Pavia S, Wilkoff B. The management of surgical complications of pacemaker and implantable cardioverter-defibrillators. Curr Opin Cardiol. 2001 Jan. 16(1):66-71. [Medline].
Johnson K. MRI Safe in Patients With Subcutaneous Defibrillators. Medscape Medical News. Available at http://www.medscape.com/viewarticle/821808. Accessed: March 17, 2014.
Rashid S, Rapacchi S, Vaseghi M, Tung R, Shivkumar K, Finn JP, et al. Improved Late Gadolinium Enhancement MR Imaging for Patients with Implanted Cardiac Devices. Radiology. 2013 Oct 1. [Medline].
Jilek C, Tzeis S, Vrazic H, et al. Safety of Screening Procedures With Hand-Held Metal Detectors Among Patients With Implanted Cardiac Rhythm Devices: A Cross-sectional Analysis. Ann Intern Med. 2011 Nov 1. 155(9):587-92. [Medline].
PRNewswire. Boston Scientific announces FDA approval of innovative new defibrillators and heart failure devices [news release]. Boston Scientific. Available at http://news.bostonscientific.com/2014-04-15-Boston-Scientific-Announces-FDA-Approval-Of-Innovative-New-Defibrillators-And-Heart-Failure-Devices. April 15, 2014; Accessed: April 27, 2014.
Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med. 2010 Jul 1. 363(1):36-44. [Medline]. [Full Text].
Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 2000 Jun 29. 342(26):1937-45. [Medline].
[Guideline] Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee t. Circulation. 2002 Oct 15. 106(16):2145-61. [Medline].
[Guideline] Gregoratos G, Cheitlin MD, Conill A, et al. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). J Am Coll Cardiol. 1998 Apr. 31(5):1175-209. [Medline].
Mirowski M. The automatic implantable cardioverter-defibrillator: an overview. J Am Coll Cardiol. 1985 Aug. 6(2):461-6. [Medline].
Myerburg RJ. Implantable cardioverter-defibrillators after myocardial infarction. N Engl J Med. 2008 Nov 20. 359(21):2245-53. [Medline].
Scott PA, Silberbauer J, McDonagh TA, et al. The impact of prolonged ICD arrhythmia detection times on outcomes: a meta-analysis. Heart Rhythm. 2014 Feb 12. [Medline].
Stiles S. Cutting Inappropriate ICD Shocks: Long Arrhythmia-Detection Time Strategy Confirmed. Medscape. Feb 21 2014. [Full Text].
Winkle RA, Mead RH, Ruder MA, et al. Long-term outcome with the automatic implantable cardioverter- defibrillator. J Am Coll Cardiol. 1989 May. 13(6):1353-61. [Medline].
US Food and Drug Administration. FDA approves first leadless pacemaker to treat heart rhythm disorders [news release]. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494417.htm. April 6, 2016; Accessed: June 2, 2016.
Maeda R, Minami Y, Haruki S, et al. Implantable cardioverter defibrillator therapy and sudden death risk stratification in hypertrophic cardiomyopathy patients with midventricular obstruction: A single-center experience. Int J Cardiol. 2016 Jul 1. 214:419-22. [Medline].
Migliore F, Silvano M, Zorzi A, et al. Implantable cardioverter defibrillator therapy in young patients with cardiomyopathies and channelopathies: a single Italian centre experience. J Cardiovasc Med (Hagerstown). 2016 Jul. 17 (7):485-93. [Medline].
Hikage T, Nojima T, Fujimoto H. Active implantable medical device EMI assessment for wireless power transfer operating in LF and HF bands. Phys Med Biol. 2016 Jun 21. 61 (12):4522-36. [Medline].
Hayashi Y, Takagi M, Kakihara J, et al. Safety and efficacy of high-rate cutoff and long detection interval ICD programming in secondary prevention patients. Heart Vessels. 2016 Jun 3. [Medline].
Maurizi N, Tanini I, Olivotto I, et al. Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2017 Mar 15. 231:115-9. [Medline].
Younes A, Al-Kindi SG, Alajaji W, Mackall JA, Oliveira GH. Presence of implantable cardioverter-defibrillators and wait-list mortality of patients supported with left ventricular assist devices as bridge to heart transplantation. Int J Cardiol. 2017 Mar 15. 231:211-215. [Medline].
Giammaria M, Cerrato E, Imazio M, Curnis A. Active implanted cardiac devices and magnetic resonance: results of a survey among cardiologists of Piedmont. J Cardiovasc Med (Hagerstown). 2017 Mar. 18 (3):185-95. [Medline].
Ip JE, Wu MS, Kennel PJ, et al. Eligibility of pacemaker patients for subcutaneous implantable cardioverter defibrillators. J Cardiovasc Electrophysiol. 2017 Feb 10. [Medline].
Farid TA, Omer MA, Gosch K, et al. Stability of pacing indices and need for pacing in cardiac transplant patients over 1 year of follow-up. J Interv Card Electrophysiol. 2017 Feb 8. [Medline].
